|
Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC). |
|
Whitney Paige Kirschbrown |
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Research Funding - Bristol-Myers Squibb |
|
|
|
|
|
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Lilly/ImClone (Inst); Merck (Inst); Sanofi/Regeneron (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical |
|
|
|
Stock and Other Ownership Interests - Genentech |
Research Funding - Genentech |
Travel, Accommodations, Expenses - Genentech |
Other Relationship - IQ CPLG Vice chair |
|
|
No Relationships to Disclose |